ROVI Pharmaceutical Laboratories

What ROVI Pharmaceutical Laboratories does

ROVI Pharmaceutical Laboratories (Laboratorios Farmacéuticos ROVI, S.A.) is a Spanish pharmaceutical company founded in 1946 and headquartered in Pozuelo de Alarcón, Madrid. The company operates through two primary business units: Specialty Pharmaceuticals, focused on proprietary in-house developed products including Bemiparina (a low molecular weight heparin/LMWH that is ROVI's principal product), biosimilars such as Enoxaparin (targeting a European market exceeding EUR 1,000 million), and prescription and hospital pharmaceuticals; and CDMO (Contract Development and Manufacturing Organization) services providing high-volume contract manufacturing across four plants for prefilled syringes and oral solid forms. The company distributes its LMWH products in 60+ countries through strategic alliances and serves pharmaceutical clients globally through its CDMO business.

ROVI's technology platform centers on proprietary pharmaceutical manufacturing (LMWH production, biosimilar development, prefilled syringes, oral solid forms) and a recently implemented comprehensive digital batch execution system using Rockwell Automation's FactoryTalk PharmaSuite MES, integrated with ROVI's ERP and LIMS platforms. The company monetizes through prescription pharmaceutical sales (Specialty Pharma segment generated EUR 473.9 million in 2025, +2% vs 2023) and contract manufacturing fees (CDMO segment generated EUR 269.5 million in 2025). FY2025 total revenue was EUR 756.1 million (-1% YoY), with EBITDA of EUR 216.2 million (+4% YoY) at a 29.1% margin. R&D spend grew 47% YoY to EUR 37.8 million. Named enterprise customers include Roche (manufacturing collaboration for a new medicine) and potentially Bristol-Myers Squibb (Phoenix site agreement).

ROVI is publicly traded on the Madrid Stock Exchange (ticker: LABFF / bme:ROVI) with 1,001-5,000 employees and offices across Spain, Germany, France, Italy, the UK, and Portugal. The company holds authorized pharmaceutical laboratory status (No. 2808E AEMPS) and is pursuing geographic expansion into North America via the April 2026 closing of a Phoenix, Arizona injectable manufacturing site acquisition from ROIS (announced September 2025, with $50 million minimum annual payments), alongside vertical expansion into AI-assisted diagnostics through majority stakes in SALI Technology and Cells IA Technologies.

Name

ROVI Pharmaceutical Laboratories

Legal name

Laboratorios Farmacéuticos ROVI, S.A.

Website

https://rovi.es

Company type

Public

Founded year

1946

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ROVI Pharmaceutical Laboratories is a Spanish pharmaceutical company operating through Specialty Pharmaceuticals (proprietary LMWH Bemiparin and biosimilars) and CDMO contract manufacturing. The publicly-listed Madrid-based company serves healthcare providers and pharmaceutical firms across 60+ countries, with FY2025 revenue of EUR 756 million.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals and CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Specialty pharmaceuticals
• Low molecular weight heparin
• Biosimilar manufacturing
• Contract development manufacturing
• Injectable pharmaceutical production

Headquarters

HQ city

Pozuelo De Alarcón

HQ country

Spain

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Specialty Pharmaceuticals: Proprietary pharmaceutical products including low molecular weight heparin (Bemiparin) and biosimilars, sold through prescription pharmaceuticals and hospital products channels.
2. CDMO (Contract Development and Manufacturing Organization): Contract manufacturing services for third parties, providing high production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ROVI Pharmaceutical Laboratories researches, develops, manufactures, and markets proprietary pharmaceutical products centered on low molecular weight heparin (Bemiparin) and biosimilars (Enoxaparin), alongside providing contract development and manufacturing (CDMO) services for prefilled syringes and oral solid forms through four manufacturing plants. Its Specialty Pharmaceutical business sells innovative own and licensed products to healthcare providers via prescription and hospital channels across more than 60 countries.

Product overview

ROVI Pharmaceutical Laboratories is a research-focused pharmaceutical company with a diversified portfolio combining proprietary and licensed products. The company's core offerings include Bemiparina (a low molecular weight heparin developed in-house as the principal product), enoxaparin biosimilars, and a broad range of prescription pharmaceuticals and hospital products. ROVI operates across the pharmaceutical value chain through two main segments: Specialty Pharmaceutical business (proprietary products protected by patents) and CDMO services (contract development and manufacturing with four plants for prefilled syringes and oral solid forms). The company maintains global presence in over 60 countries through strategic alliances, with manufacturing capabilities spanning both proprietary products and third-party manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• CDMO: Contract manufacturing organization services for prefilled syringes and oral solid forms
• Bemiparina
• Biosimilars

Products and services

• Bemiparina (Low Molecular Weight Heparin) ROVI's principal proprietary low-molecular-weight heparin developed in-house, serving as a key anticoagulant therapy sold through prescription and hospital channels across 60+ countries.
• Enoxaparin Biosimilar Biosimilar version of enoxaparin positioned as a major growth product targeting a European market exceeding EUR 1,000 million.
• Prescription Pharmaceuticals Portfolio Diversified portfolio of innovative proprietary and licensed pharmaceutical products protected by patents, distributed through prescription channels to healthcare providers and hospitals.
• Hospital Products Pharmaceutical products specifically formulated and marketed for hospital use, sold through the hospital products division.
• CDMO (Contract Development and Manufacturing Organization) Services Contract development and manufacturing services for third-party pharmaceutical companies, providing high production capacity across four manufacturing plants for prefilled syringes and oral solid dosage forms.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core, supporting and strategic.

• Rockwell AutomationcoreTechnology or Integration · 12 March 2026Rockwell Automation collaborated with ROVI to implement a comprehensive digital batch execution system using FactoryTalk PharmaSuite MES. The project, completed in under a year with support from integrator Adasoft, transitioned ROVI from paper-based records to a fully digital environment, connecting ERP and LIMS platforms. Results include improved traceability, reduced review times, and enhanced operational competitiveness. The standardized approach serves as a foundation for future digital rollouts across additional ROVI facilities.
• AdasoftsupportingImplementation/ SI/ Consulting Partner · 12 March 2026Adasoft served as the system integrator supporting the implementation of Rockwell Automation's FactoryTalk PharmaSuite MES at ROVI's pharmaceutical manufacturing facilities.
• RochecoreStrategic or Co-development Partner · 1 January 2025Rovi announced a collaboration with Roche for manufacturing a new medicine, representing a strategic partnership for contract manufacturing services.
• ROIScoreStrategic or Co-development Partner · 1 January 2025Rovi acquired a Phoenix-based injectable manufacturing site from ROIS for $50 million minimum annual payments, with a potential Bristol-Myers Squibb manufacturing agreement.
• SALI TechnologystrategicStrategic or Co-development Partner · 1 January 2025Rovi acquired a majority stake in AI-assisted diagnostics company SALI Technology, representing expansion into AI-assisted diagnostics.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Almirall: Spanish specialty pharmaceutical company listed on the Barcelona Stock Exchange with a comparable European focus on prescription and specialty products. Almirall's size, regional footprint, and specialty pharma orientation make it a close structural peer to ROVI.
• Faes Farma: Spanish specialty pharmaceutical company operating in prescription pharmaceuticals, hospital products, and contract manufacturing, with comparable geographic concentration in Spain and Europe. Direct overlap with ROVI in prescription specialty pharma and CDMO-style services.
• Recipharm: European CDMO with prefilled syringe, sterile fill-finish, and oral solid dose capabilities serving global pharma clients. Closely mirrors ROVI's CDMO service offering across dosage forms and customer profile.
• Hovione: Portugal-headquartered CDMO with integrated drug substance and drug product capabilities, including sterile injectables and oral dosage forms. Comparable European footprint and small-molecule CDMO scope to ROVI.
• Siegfried Holding: Swiss-listed CDMO offering API and finished drug product manufacturing including sterile and oral solid dose forms. Comparable scale, European base, and integrated small-molecule CDMO positioning to ROVI.

Broad incumbents

• Sanofi: Global pharmaceutical major whose Lovenox/Clexane (enoxaparin) franchise directly competes with ROVI's Bemiparin (LMWH) and faces the same biosimilar pressure ROVI is targeting with its enoxaparin biosimilar.
• Catalent: Global CDMO leader with deep capabilities in prefilled syringes, biologics fill-finish, and oral solid dose manufacturing. Directly comparable to ROVI's CDMO service line at a larger global scale.
• Lonza Group: Swiss-listed global CDMO leader across small molecules, biologics, and cell & gene services. Overlaps with ROVI's CDMO ambitions, particularly in injectable and small-molecule drug product manufacturing.
• Teva Pharmaceutical: Global specialty and biosimilars major with extensive European presence. Competes with ROVI in biosimilars and specialty pharmaceuticals, including overlapping therapeutic areas such as anticoagulants.
• Pfizer: Global pharmaceutical major whose Fragmin (dalteparin) LMWH franchise competes directly with Bemiparin in the anticoagulant market, and whose contract manufacturing operations overlap with ROVI's CDMO service line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rovi_ir
• YouTubeyoutube.com/channel/UC8F4xv-4uEPYW_qvPxPsAhw/featured?view_as=subscriber
• LinkedInlinkedin.com/company/pharmaceutical-laboratories-rovi

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ROVI Pharmaceutical Laboratories